Jefferies Group Reaffirms Underperform Rating for Hikma Pharmaceuticals (HIK)
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “underperform” rating reiterated by research analysts at Jefferies Group in a report released on Wednesday. They presently have a GBX 895 ($12.14) target price on the stock. Jefferies Group’s price objective indicates a potential downside of 10.68% from the company’s previous close.
A number of other brokerages have also commented on HIK. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.34) to GBX 1,250 ($16.95) and set a “neutral” rating on the stock in a research report on Friday, October 6th. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, October 31st. Numis Securities reissued a “buy” rating and issued a GBX 1,300 ($17.63) price objective on shares of Hikma Pharmaceuticals in a research report on Wednesday, December 20th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Finally, cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating on the stock in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of GBX 1,171 ($15.88).
Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,002 ($13.59) on Wednesday. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.29) and a one year high of GBX 2,346 ($31.81). The firm has a market cap of $2,410.00 and a P/E ratio of 2,004.00.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.